Could less be more? new trial tests lighter hormone therapy for prostate cancer
NCT ID NCT06369610
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing whether giving fewer hormone therapy drugs (abiraterone acetate and GnRH analogs) along with radiation can work as well as longer treatment for high-risk prostate cancer that has spread a little. The goal is to reduce side effects while still controlling the cancer. About 110 participants will receive a risk-tailored, shorter course of hormone therapy plus radiation.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
abiraterone acetate (Zytiga) and gonadotropin-releasing hormone analogs
What this could lead to
If successful, this could show that a shorter, less intense hormone therapy combined with radiation is just as effective as longer treatment, with fewer side effects for high-risk prostate cancer patients.
What could go wrong
This is a phase 2 trial with only 110 participants, so results are preliminary. It may not prove that de-escalated treatment is as effective as standard care, and some patients might still need more intensive therapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Mayo Clinic in Arizona
RECRUITINGScottsdale, Arizona, 85259, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••